Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Eli Lilly & Co, retaining the price target of $840.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Eli Lilly & Co’s promising future. The recent publication of the ATTAIN-1 study in the New England Journal of Medicine provides a positive outlook for Lilly, despite some efficacy challenges due to the demographic composition of the trial participants. The study’s results indicate that while the efficacy of orforglipron was slightly reduced in Hispanic and male patients, the overall data supports the drug’s competitive profile and its potential for long-term use.
Additionally, the tolerability of orforglipron appears favorable, with gastrointestinal symptoms diminishing over time, making it suitable for chronic use. Furthermore, Eli Lilly’s robust pipeline, including the recent approval of donanemab, and its strong position in the diabetes and oncology sectors, underpin the company’s growth prospects. These factors collectively support Seigerman’s confidence in the stock’s potential for outperforming its peers.
In another report released today, Citi also maintained a Buy rating on the stock with a $1,190.00 price target.